

CSIM Annual Meeting 2024

Evidence of Conflict of Financial Interest

Planning Committee

| Last Name | First Name | Declaration |
|-----------|-------------|--|
| Willem | Blois | No conflicts to declare. |
| Lori | Israelian | No conflicts to declare. |
| Gurpreet | Jaswal | No conflicts to declare. |
| Emily | Jones | No conflicts to declare. |
| Jorin | LindenSmith | No conflicts to declare. |
| Clara | Lu | No conflicts to declare. |
| Kim | Moore | No conflicts to declare. |
| Kathryn | Myers | Clinical Trials multicentre participant: CIHR |
| Mohamed | Panju | No conflicts to declare. |
| Jeffrey | Schaefer | Moderator honoraria at educational events: Bayer, Boehringer Ingelheim, Novartis, Pfizer |
| Steve | Shadowitz | No conflicts to declare. |
| Erin | Spicer | Research salary support: Academic Medical Organization of Southwestern Ontario (AMOSO) |

| | | |
|---------------------|-----------------|---|
| Kajenny | Srivaratharajah | No conflicts to declare. |
| Allen | Tran | Funded grants: Royal College of Physicians and Surgeons of Canada, Canadian Society of Internal Medicine, |
| Don Thiwanka | Wijeratne | No conflicts to declare. |
| Ahraaz | Wyne | No conflicts to declare. |

Faculty

| Last Name | First Name | Declaration |
|----------------------|------------|--|
| Abu-Hilal | Mohannad | No conflicts to declare |
| Ades | Matthew | Honoraria: Novo Nordisk |
| Anand | Sonia | Consulting and speaker fees: Bayer AG, Janssen Pharmaceuticals, Daiichi Sankyo, Novartis and Novo Nordisk |
| Antiperovitch | Pavel | No conflicts to declare |
| Appleton | Andrew | No conflicts to declare. Discussion of new/proprietary tech: Use of apps including Trainerize and Eat This Much as examples of ways to deliver fitness and diet advice and tracking for patients. The speaker has no affiliation with either of these apps or their companies. |
| Bates | Shannon | Honoraria: Leo Pharma Canada, Inc; ROVI; Sanofi Payment for work as Co-Editor in Chief of Thrombosis Research from Elsevier Advisory board: Foundation for Women and Girls with Blood Disorders (non-profit organization, no payment.) CIHR: Co-investigator |
| Bowdridge | Joshua | No conflicts to declare |
| Breadner | Daniel | Honoraria: AstraZeneca, Amgen, Roche, Merck, Bayer, Bristol-Myers Squibb, Takeda Advisory Boards: BeiGene, Guardant Health, AstraZeneca, Amgen and Boehringer Ingelheim Study funding, fellowship support or drug in-kind support for studies: AstraZeneca, Pfizer, Merck, Takeda, BeiGene Advisor and stock option: Need |
| Burrell | Alishya | No conflicts to declare |

| | | |
|------------------------|------------|--|
| Cameron | Paul | No conflicts to declare |
| Carlin | Stephanie | Honoraria/speaker fees: BMS/Pfizer, Fresenius Kabi, Leo Pharma Advisory boards: Astrazeneca, Fresenius Kabi, Leo Pharma, Servier Off-label use discussion: PCC for DOAC-associated major/life-threatening bleeding |
| Cavalcanti | Rodrigo | No conflicts to declare |
| Clark | Heather | Honoraria: The Ottawa Hospital |
| Conen | Dave | No conflicts to declare |
| Demers | Catherine | Honoraria: Sanofi Consultant meeting: Novo Nordisk Research funding - Principal Investigator Trial: Merck, BMS, NovoNordisk |
| Dev | Shelly | No conflicts to declare |
| Devereaux | PJ | Member, Advisory Board: Bayer, Quidel Canada Grant Funding: Abbott Diagnostics, AOP Pharma, Roche Diagnostics, Siemens Patents on Monitoring Devices: CloudDX, Philips Healthcare Consultant: Abbott Diagnostics, Astra Zeneca, Renibus, Roche Canada, Trimedica |
| Duceppe | Emmanuelle | Research grants: Roche Diagnostics; Abbott Laboratories |
| Ernst | Jaclyn | Meeting consultant: Bausch Health, Novo Nordisk Recipient of pharmaceutical samples: Novo Nordisk |
| Evans | Gerald | Honoraria, Travel expenses: Moderna Australia Member, Expert Advisory Committee: Reformulary Inc. |
| Fayowski | Cassie | Trade names used: Adalat/Nifedipine XL (for clarity) |
| Frost | David | No conflicts to declare |
| Gaudreau-Simard | Mathilde | Grants: The Ottawa Hospital Academic Medical Association |
| Gerstein | Hertzel | Honoraria: AstraZeneca, Eli Lilly, Novo Nordisk, DKSH, Zuellig, Sanofi, Carbon Brand, and Jiangsu Hanson Advisory boards and consulting: Abbott, Bayer, Eli Lilly, Novo Nordisk, Pfizer, Sanofi, Kowa, and Hanmi Research or CME grants: Eli Lilly, AstraZeneca, Novo Nordisk, Hanmi, Abbott, Boehringer Ingelheim |
| Hanmiah | Rajendar | No conflicts to declare |

| | | |
|-----------------------|---------|---|
| Hudson | David | No conflicts to declare |
| Hwang | Stephen | Peer-reviewed research grant: CIHR |
| Jones | Emily | No conflicts to declare |
| Joseph | Radha | No conflicts to declare |
| Kapoor | Andrew | Honoraria: Gilead, ViiV |
| Kessler Borges | Flavia | Honoraria: Roche Diagnostics Investigator initiated study: CIHR, HAHSO, NIH, Roche Diagnostics |
| Kohli | Sonny | Director, Clinical Science (Khure Health); Board Member (Halo Health) Medical Advisor (RegenaLife, Lifestyle Rx) Patent: US10,893,837 B2 SIMULTANEOUS MULTI-PARAMETER PHYSIOLOGICAL MONITORING DEVICE WITH LOCAL AND REMOTE ANALYTICAL CAPABILITY |
| Kuper | Ayelet | President (2024-2026): AMEE: The International Association for Health Professions Education |
| Lu | Clara | No conflicts to declare. Trade names: (e.g. Suboxone, Kadian) once and in brackets after introducing the generic name, as these trade names may be more familiar to the audience. Off-label use discussion: therapies which are well established in Canadian addictions guidelines and widely adopted across Canada: 1) Buprenorphine microdosing protocols; 2) sustained release oral morphine for opioid use disorder . |
| Luo | Owen | Resident Physician Advisor: Canadian Coalition of Green Healthcare Research grant funding from Health Canada and the McGill Department of Medicine in planetary health medical education |
| Ma | Irene | Honoraria: Cornell University, ACP, AIUM, CSIM, Sonography Canada, International Pediatric Nephrology Association, University of Colorado Advisory boards: AIUM, ACP |
| MacMillan | Thomas | No conflicts to declare |
| Marcucci | Maura | Grants: CIHR; National Health and Medical Research Council, Funding Schemes, NHMRC Project Grant 1162362, Australia; and General Research Fund 14104419, Research Grant Council, Hong Kong SAR, China; PHRI (Canada); Hamilton Health Sciences Research Institute; Roche Diagnostics International Ltd |

| | | |
|------------------|------------------|--|
| Martin | Leslie | Grant for research looking at 1) program development for patients with infectious complications of substance use 2) program evaluation for substance use services 3) Entrustable professional activities as learning cues: HAHSO grant, Peter Boris Centre for Addictions Medicine Living Laboratory Grant, Education Scholarship Fund |
| Merali | Zahra | No conflicts to declare |
| Milne | Kathleen | No conflicts to declare Off-label use discussion: Some medications for symptom management in palliative care are off label. Examples include nabilone for neuropathic pain, and olanzapine for nausea/vomiting. |
| Mirza | Reza | Funded a grant for RA-ILD: BMS |
| Molnar | Amber | Research funding: CIHR, Kidney Foundation of Canada, McMaster University Department of Medicine |
| Montague | Steven | No conflicts to declare |
| Moore | Ginette | Honoraria: Teva, AbbVie, UCB, Mastermind Canada Advisory boards: Palladin, Teva Off-label use discussion: Medications when discussing headache management in pregnancy |
| Nerenberg | Kara | Research grant funding: Heart & Stroke Canada; CIHR; Alberta Innovates |
| Oczkowski | Simon | Travel support: Fisher & Paykel Healthcare Co-investigator: CIHR |
| Ofori | Sandra | No conflicts to declare |
| Quinn | Kieran | Clinician-Scientist Salary Support: Sinai Health Research grants: CIHR, Long COVID Web, Health Canada, University of Toronto |
| Raghavan | Natya | Honoraria: Astra Zeneca, Glaxo-Smith-Klein Research support: Boeringer Ingelheim |
| Rashid | Meb | No conflicts to declare |
| Roshanov | Pavel | Off-label use discussion: Tranexamic acid, desmopressin |
| Sahlas | Demetrios | <i>Not yet provided</i> |
| Sandre | Anthony | Honoraria: NovoNordisk |

| | | |
|-----------------|--------------|--|
| Sattin | Michael | No conflicts to declare |
| Schaefer | Jeffrey | Moderator honoraria at educational events: Bayer, Boehringer Ingelheim, Novartis, Pfizer |
| Shetty | Nabha | <i>Advisor: Canadian coalition of green healthcare</i> Spark grant funding for green mtu planetary health education: CASCADES |
| Spicer | Erin | Research salary support: Academic Medical Organization of Southwestern Ontario (AMOSO) |
| Tandon | Vikas | No conflicts to declare |
| Tselios | Konstantinos | Advisory board, speakers' bureau, grants, trials: Astra Zeneca, GSK, Novartis, Roche, UCB, Fresenius Kabi, Lupus Ontario, CITE, CIHR |
| Turnbull | Jeffrey | Consulting: MOH Nova Scotia, MOH Ontario, Coroner's Office Ontario |
| Wang | Michael | Funded grants or clinical trials: HAHSO AFP Innovation Fund; CIHR |
| Wong | Sherwin | No conflicts to declare |
| Yu | Jeffrey | Honorarium: Canadian Resuscitative Ultrasound Course |

At October 11, 2024